Patents Assigned to Sublimity Therapeutics Limited
-
Publication number: 20240115657Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.Type: ApplicationFiled: April 19, 2023Publication date: April 11, 2024Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
-
Publication number: 20240100122Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: April 19, 2023Publication date: March 28, 2024Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Bernard Francis McDonald, Monica Rosa
-
Publication number: 20240091304Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: July 24, 2023Publication date: March 21, 2024Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Monica Rosa
-
Publication number: 20240082349Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and coating. The invention also related to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: June 5, 2023Publication date: March 14, 2024Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa, Dáire O'Donnell, Wyatt Renaud of Calhane
-
Publication number: 20220080026Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: April 30, 2021Publication date: March 17, 2022Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Bernard Francis McDonald, Monica Rosa
-
Publication number: 20220062374Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: March 29, 2021Publication date: March 3, 2022Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa, Dáire O'Donnell, Wyatt Renaud of Calhane
-
Publication number: 20210386817Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: January 7, 2021Publication date: December 16, 2021Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Monica Rosa
-
Publication number: 20210338768Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.Type: ApplicationFiled: December 10, 2020Publication date: November 4, 2021Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
-
Patent number: 10993987Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: GrantFiled: November 6, 2015Date of Patent: May 4, 2021Assignee: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa, Dáire O'Donnell, Wyatt Renaud of Calhane
-
Publication number: 20200171123Abstract: An oral modified release composition comprising cyclosporin, wherein the composition is for use in the treatment of ulcerative colitis in a patient, wherein the composition is for use in the concurrent treatment of the patient with an active agent selected from an aminosalicylate and a steroid, and a fixed or free combination thereof. Also claimed are kits comprising the oral modified release composition and the active agent. Also disclosed are methods for the treatment of ulcerative colitis using the oral modified release composition.Type: ApplicationFiled: February 3, 2020Publication date: June 4, 2020Applicant: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Publication number: 20200009219Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.Type: ApplicationFiled: July 31, 2019Publication date: January 9, 2020Applicant: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Publication number: 20200009218Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency.Type: ApplicationFiled: July 11, 2019Publication date: January 9, 2020Applicant: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Publication number: 20190381131Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: July 2, 2019Publication date: December 19, 2019Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
-
Patent number: 10434139Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.Type: GrantFiled: January 19, 2017Date of Patent: October 8, 2019Assignee: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Patent number: 10434138Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: GrantFiled: November 7, 2014Date of Patent: October 8, 2019Assignee: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
-
Patent number: 10434140Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.Type: GrantFiled: May 16, 2017Date of Patent: October 8, 2019Assignee: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Publication number: 20190192619Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: November 16, 2018Publication date: June 27, 2019Applicant: Sublimity Therapeutics LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa